ReviewMolecular cancer2026
Beyond Darwin: reactive heredity, burst-drift dynamics and eco‑evolutionary control of cancer.
Review in Molecular cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Darwinian clonal evolution provides a necessary framework for understanding tumour progression, yet emerging evidence shows that some cancers depart from a strictly gradualist tempo through episodic "macroevolutionary" leaps. We propose a unifying Burst-Drift-Control (BDC) model in which short-lived genomic reconfigurations ("bursts") that transiently alter heritable genomic states ("reactive heredity") precede longer intervals of constrained expansion, creating time-bounded vulnerabilities that clinicians may strategically steer ("control"). In this usage, the Drift component refers specifically to a drift-dominated or weak-selection interval after any initial post-burst sorting, not to the selective sweep itself. In the Burst phase, single catastrophic events, such as extrachromosomal DNA amplifications, chromothripsis, chromoplexy or whole-genome doubling, can generate major shifts in genotype and phenotype. These bursts produce new genetic configurations and can increase evolvability, for example when ecDNA circles permit oncogene dose tuning and non-Mendelian inheritance. During the drift-dominated interval, tumours may enter longer periods of constrained or near-neutral expansion in which spatial structure, clonal interference and weak or unresolved selection allow multiple lineages to persist, although the prevalence of such dynamics varies substantially by tumour type and treatment context. BDC does not assume that selective advantage is higher immediately after a burst than at later time points; later therapy or microenvironmental change can also impose strong selection. Finally, in the Control phase, if therapy is timed to exploit ecological dependencies and the fitness costs of resistance, cancer growth may be restrained as a stable, polyclonal "oligopoly" rather than progressing rapidly to an aggressive monoclonal takeover. We discuss supporting evidence, counterexamples and practical limitations, and argue that the main value of BDC lies in linking punctuated genome change to testable windows for evolutionary steering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.